American Renal Associates (ARA) Releases Earnings Results

Share on StockTwits

American Renal Associates (NYSE:ARA) issued its earnings results on Thursday. The company reported $0.19 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.13 by $0.06, Briefing.com reports. The firm had revenue of $211.02 million for the quarter, compared to the consensus estimate of $217.15 million. American Renal Associates had a positive return on equity of 19.60% and a negative net margin of 1.11%. The company’s revenue was up 12.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.19 EPS.

NYSE ARA opened at $17.50 on Friday. The company has a debt-to-equity ratio of 5.30, a quick ratio of 1.04 and a current ratio of 1.07. American Renal Associates has a twelve month low of $9.91 and a twelve month high of $24.07. The firm has a market cap of $667.52 million, a P/E ratio of 28.69, a PEG ratio of 3.63 and a beta of 2.09.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its holdings in shares of American Renal Associates by 17.1% during the 3rd quarter. BlackRock Inc. now owns 955,892 shares of the company’s stock valued at $20,693,000 after acquiring an additional 139,789 shares in the last quarter. Seizert Capital Partners LLC boosted its holdings in shares of American Renal Associates by 69.3% during the 3rd quarter. Seizert Capital Partners LLC now owns 37,903 shares of the company’s stock valued at $821,000 after acquiring an additional 15,519 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of American Renal Associates by 6.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 56,098 shares of the company’s stock valued at $1,215,000 after acquiring an additional 3,365 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of American Renal Associates by 1.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 691,555 shares of the company’s stock valued at $14,972,000 after acquiring an additional 12,549 shares in the last quarter. Finally, Cadence Capital Management LLC boosted its holdings in shares of American Renal Associates by 91.4% during the 3rd quarter. Cadence Capital Management LLC now owns 129,802 shares of the company’s stock valued at $2,810,000 after acquiring an additional 61,994 shares in the last quarter. 92.67% of the stock is currently owned by institutional investors.

A number of equities research analysts have weighed in on the company. Zacks Investment Research downgraded American Renal Associates from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 23rd. SunTrust Banks reaffirmed a “buy” rating and issued a $25.00 target price on shares of American Renal Associates in a report on Thursday, August 9th. Goldman Sachs Group assumed coverage on American Renal Associates in a report on Thursday, July 19th. They issued a “neutral” rating and a $16.00 target price on the stock. Leerink Swann raised American Renal Associates from a “market perform” rating to an “outperform” rating and raised their target price for the company from $22.00 to $26.00 in a report on Thursday, August 23rd. Finally, ValuEngine raised American Renal Associates from a “hold” rating to a “buy” rating in a report on Friday, August 3rd. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $22.60.

COPYRIGHT VIOLATION NOTICE: “American Renal Associates (ARA) Releases Earnings Results” was first posted by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://weekherald.com/2018/11/10/american-renal-associates-ara-releases-earnings-results.html.

About American Renal Associates

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

Featured Story: Benefits of owning preferred stock

Earnings History for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply